International Tables for Crystallography (2012). Vol. F. ch. 1.3, pp. 13-38   | 1 | 2 |
https://doi.org/10.1107/97809553602060000806

Chapter 1.3. Macromolecular crystallography and medicine

Contents

  • 1.3. Macromolecular crystallography and medicine  (pp. 13-38) | html | pdf | chapter contents |
    W. G. J. Hol and C. L. M. J. Verlinde
    • 1.3.1. Introduction  (p. 13) | html | pdf |
    • 1.3.2. Crystallography and medicine  (pp. 13-14) | html | pdf |
    • 1.3.3. Crystallography and genetic diseases  (pp. 14-15) | html | pdf |
    • 1.3.4. Crystallography and development of novel pharmaceuticals  (pp. 15-26) | html | pdf |
      • 1.3.4.1. Infectious diseases  (pp. 16-18) | html | pdf |
        • 1.3.4.1.1. Viral diseases  (p. 16) | html | pdf |
        • 1.3.4.1.2. Bacterial diseases  (p. 16) | html | pdf |
        • 1.3.4.1.3. Protozoan infections  (pp. 16-17) | html | pdf |
        • 1.3.4.1.4. Fungi  (pp. 17-18) | html | pdf |
        • 1.3.4.1.5. Helminths  (p. 18) | html | pdf |
      • 1.3.4.2. Resistance  (pp. 18-22) | html | pdf |
      • 1.3.4.3. Non-communicable diseases  (pp. 22-25) | html | pdf |
        • 1.3.4.3.1. Cancers  (pp. 22-23) | html | pdf |
        • 1.3.4.3.2. Diabetes  (p. 23) | html | pdf |
        • 1.3.4.3.3. Blindness  (p. 23) | html | pdf |
        • 1.3.4.3.4. Cardiovascular disorders  (p. 23) | html | pdf |
        • 1.3.4.3.5. Neurological disorders  (pp. 23-25) | html | pdf |
      • 1.3.4.4. Drug metabolism and crystallography  (p. 25) | html | pdf |
      • 1.3.4.5. Drug manufacturing and crystallography  (pp. 25-26) | html | pdf |
    • 1.3.5. Vaccines, immunology and crystallography  (p. 26) | html | pdf |
    • 1.3.6. Outlook and dreams  (pp. 26-27) | html | pdf |
    • References | html | pdf |
    • Figures
      • Fig. 1.3.4.1. The structure-based drug design cycle  (p. 16) | html | pdf |
    • Tables
      • Table 1.3.3.1. Crystal structures and genetic diseases  (p. 14) | html | pdf |
      • Table 1.3.4.1. Important human pathogenic viruses and their proteins  (pp. 17-18) | html | pdf |
      • Table 1.3.4.2. Protein structures of important human pathogenic bacteria  (pp. 19-20) | html | pdf |
      • Table 1.3.4.3. Protein structures of important human pathogenic protozoa, fungi and helminths  (pp. 21-22) | html | pdf |
      • Table 1.3.4.4. Mechanisms of resistance  (p. 23) | html | pdf |
      • Table 1.3.4.5. Important human protein structures in drug design  (pp. 24-25) | html | pdf |